HC Wainwright Begins Coverage on Replimune Group (NASDAQ:REPL)
HC Wainwright started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $26.00 target price on the stock.
REPL has been the topic of a number of other reports. Wedbush reduced their price target on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an outperform rating on the stock in a report on Wednesday, April 24th. Zacks Investment Research upgraded shares of HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. Six equities research analysts have rated the stock with a buy rating, Replimune Group presently has a consensus rating of Buy and a consensus price target of $24.67.
NASDAQ:REPL opened at $13.13 on Monday. The firm’s 50 day moving average price is $13.57. Replimune Group has a 52 week low of $8.88 and a 52 week high of $23.55. The company has a current ratio of 14.26, a quick ratio of 14.26 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $441.08 million and a PE ratio of -9.87.
Replimune Group Company Profile
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Article: What is the downside to momentum investing?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.